Every Vaccine and Treatment in Development for COVID-19
As the number of confirmed COVID-19 cases continues to skyrocket, healthcare researchers around the world are working tirelessly to discover new life-saving medical innovations.
The projects these companies are working on can be organized into three distinct groups:
- Diagnostics: Quickly and effectively detecting the disease in the first place
- Treatments: Alleviating symptoms so people who have disease experience milder symptoms, and lowering the overall mortality rate
- Vaccines: Preventing transmission by making the population immune to COVID-19
Today’s graphics provide an in-depth look at who’s in the innovation race to defeat the virus, and they come to us courtesy of Artis Ventures, a venture capital firm focused on life sciences and tech investments.
Editor’s note: R&D is moving fast on COVID-19, and the situation is quite fluid. While today’s post is believed to be an accurate snapshot of all innovations and developments listed by WHO and FDA as of March 30, 2020, it is possible that more data will become available.
Knowledge is Power
Testing rates during this pandemic have been a point of contention. Without widespread testing, it has been tough to accurately track the spread of the virus, as well as pin down important metrics such as infectiousness and mortality rates. Inexpensive test kits that offer quick results will be key to curbing the outbreak.
Here are the companies and institutions developing new tests for COVID-19:
The ultimate aim of companies like Abbott and BioFire Defense is to create a test that can produce accurate results in as little as a few minutes.
In the Trenches With Coronavirus
While the majority of people infected with COVID-19 only experience minor symptoms, the disease can cause severe issues in some cases – even resulting in death. Most of the forms of treatment being pursued fall into one of two categories:
- Treating respiratory symptoms – especially the inflammation that occurs in severe cases
- Antiviral growth – essentially stopping viruses from multiplying inside the human body
Here are the companies and institutions developing new treatment options for COVID-19:
A wide range of players are in the race to develop treatments related to COVID-19. Pharma and healthcare companies are in the mix, as well as universities and institutes.
One surprising name on the list is Fujifilm. The Japanese company’s stock recently shot up on the news that Avigan, a decades-old flu drug developed through Fujifilm’s healthcare subsidiary, might be effective at helping coronavirus patients recover. The Japanese government’s stockpile of the drug is reportedly enough to treat two million people.
The progress that is perhaps being watched the closest by the general public is the development of a COVID-19 vaccine.
Creating a safe vaccine for a new illness is no easy feat. Thankfully, rapid progress is being made for a variety of reasons, including China’s efforts to sequence the genetic material of Sars-CoV-2 and to share that information with research groups around the world.
Another factor contributing to the unprecedented speed of development is the fact that coronaviruses were already on the radar of health science researchers. Both SARS and MERS were caused by coronaviruses, and even though vaccines were shelved once those outbreaks were contained, learnings can still be applied to defeating COVID-19.
One of the most promising leads on a COVID-19 vaccine is mRNA-1273. This vaccine, developed by Moderna Therapeutics, is being developed with extreme urgency, skipping straight into human trials before it was even tested in animals. If all goes well with the trials currently underway in Washington State, the company hopes to have an early version of the vaccine ready by fall 2020. The earliest versions of the vaccine would be made available to at-risk groups such as healthcare workers.
Further down the pipeline are 15 types of subunit vaccines. This method of vaccination uses a fragment of a pathogen, typically a surface protein, to trigger an immune response, teaching the body’s immune system how to fight off the disease without actually introducing live pathogens.
No Clear Finish Line
Unfortunately, there is no silver bullet for solving this pandemic.
A likely scenario is that teams of researchers around the world will come up with solutions that will incrementally help stop the spread of the virus, mitigate symptoms for those infected, and help lower the overall death toll. As well, early solutions rushed to market will need to be refined over the coming months.
We can only hope that the hard lessons learned from fighting COVID-19 will help stop a future outbreak in its tracks before it becomes a pandemic. For now, those of us on the sideline can only do our best to flatten the curve.
The Road to Recovery: Which Economies are Reopening?
We look at mobility rates as well as COVID-19 recovery rates for 41 economies, to see which countries are reopening for business.
The Road to Recovery: Which Economies are Reopening?
COVID-19 has brought the world to a halt—but after months of uncertainty, it seems that the situation is slowly taking a turn for the better.
Today’s chart measures the extent to which 41 major economies are reopening, by plotting two metrics for each country: the mobility rate and the COVID-19 recovery rate:
- Mobility Index
This refers to the change in activity around workplaces, subtracting activity around residences, measured as a percentage deviation from the baseline.
- COVID-19 Recovery Rate
The number of recovered cases in a country is measured as the percentage of total cases.
Data for the first measure comes from Google’s COVID-19 Community Mobility Reports, which relies on aggregated, anonymous location history data from individuals. Note that China does not show up in the graphic as the government bans Google services.
COVID-19 recovery rates rely on values from CoronaTracker, using aggregated information from multiple global and governmental databases such as WHO and CDC.
Reopening Economies, One Step at a Time
In general, the higher the mobility rate, the more economic activity this signifies. In most cases, mobility rate also correlates with a higher rate of recovered people in the population.
Here’s how these countries fare based on the above metrics.
|Country||Mobility Rate||Recovery Rate||Total Cases||Total Recovered|
Mobility data as of May 21, 2020 (Latest available). COVID-19 case data as of May 29, 2020.
In the main scatterplot visualization, we’ve taken things a step further, assigning these countries into four distinct quadrants:
1. High Mobility, High Recovery
High recovery rates are resulting in lifted restrictions for countries in this quadrant, and people are steadily returning to work.
New Zealand has earned praise for its early and effective pandemic response, allowing it to curtail the total number of cases. This has resulted in a 98% recovery rate, the highest of all countries. After almost 50 days of lockdown, the government is recommending a flexible four-day work week to boost the economy back up.
2. High Mobility, Low Recovery
Despite low COVID-19 related recoveries, mobility rates of countries in this quadrant remain higher than average. Some countries have loosened lockdown measures, while others did not have strict measures in place to begin with.
Brazil is an interesting case study to consider here. After deferring lockdown decisions to state and local levels, the country is now averaging the highest number of daily cases out of any country. On May 28th, for example, the country had 24,151 new cases and 1,067 new deaths.
3. Low Mobility, High Recovery
Countries in this quadrant are playing it safe, and holding off on reopening their economies until the population has fully recovered.
Italy, the once-epicenter for the crisis in Europe is understandably wary of cases rising back up to critical levels. As a result, it has opted to keep its activity to a minimum to try and boost the 65% recovery rate, even as it slowly emerges from over 10 weeks of lockdown.
4. Low Mobility, Low Recovery
Last but not least, people in these countries are cautiously remaining indoors as their governments continue to work on crisis response.
With a low 0.05% recovery rate, the United Kingdom has no immediate plans to reopen. A two-week lag time in reporting discharged patients from NHS services may also be contributing to this low number. Although new cases are leveling off, the country has the highest coronavirus-caused death toll across Europe.
The U.S. also sits in this quadrant with over 1.7 million cases and counting. Recently, some states have opted to ease restrictions on social and business activity, which could potentially result in case numbers climbing back up.
Over in Sweden, a controversial herd immunity strategy meant that the country continued business as usual amid the rest of Europe’s heightened regulations. Sweden’s COVID-19 recovery rate sits at only 13.9%, and the country’s -93% mobility rate implies that people have been taking their own precautions.
COVID-19’s Impact on the Future
It’s important to note that a “second wave” of new cases could upend plans to reopen economies. As countries reckon with these competing risks of health and economic activity, there is no clear answer around the right path to take.
COVID-19 is a catalyst for an entirely different future, but interestingly, it’s one that has been in the works for a while.
Without being melodramatic, COVID-19 is like the last nail in the coffin of globalization…The 2008-2009 crisis gave globalization a big hit, as did Brexit, as did the U.S.-China trade war, but COVID is taking it to a new level.
—Carmen Reinhart, incoming Chief Economist for the World Bank
Will there be any chance of returning to “normal” as we know it?
Charting the Rise and Fall of the Global Luxury Goods Market
This infographic charts the rise and fall of the $308 billion global personal luxury market, and explores what the coming year holds for its growth
The Rise and Fall of the Global Luxury Goods Market
Global demand for personal luxury goods has been steadily increasing for decades, resulting in an industry worth $308 billion in 2019.
However, the insatiable desire for consumers to own nice things was suddenly interrupted by the coming of COVID-19, and experts are predicting a brutal contraction of up to one-third of the current luxury good market size this year.
Will the industry bounce back? Or will it return as something noticeably different?
A Once Promising Trajectory
The global luxury goods market—which includes beauty, apparel, and accessories—has compounded at a 6% pace since the 1990s.
Recent years of growth in the personal luxury goods market can be mostly attributed to Chinese consumers. This geographic market accounted for 90% of total sales growth in 2019, followed by the Europe and the Americas.
Analysts suggest that China’s younger luxury goods consumers in particular have significant spending power, with an average spend of $6,000 (¥41,000) per person in pre-COVID times.
An Industry Now in Distress
The lethal combination of reduced foot traffic and decreased consumer spending in the first quarter of 2020 has brought the retail industry to its knees.
In fact, more than 80% of fashion and luxury players will experience financial distress as a result of extended store closures.
With iconic luxury retailers such as Neiman Marcus filing for bankruptcy, the pressure on the luxury industry is clear. It should be noted however, that companies who were experiencing distress before the COVID-19 outbreak will be the hardest hit.
Predicting the Collapse
In a recent report, Bain & Company estimated a 25% to 30% global luxury market contraction for the first quarter of 2020 based on several economic variables. They have also modeled three scenarios to predict the performance for the remainder of 2020.
- Optimistic scenario: A limited market contraction of 15% to 18%, assuming increased consumer demand for the second and third quarter of the year, roughly equating to a sales decline of $46 billion to $56 billion.
- Intermediate scenario: A moderate market contraction of between 22% and 25%, or $68 to $77 billion.
- Worst-case scenario: A steep contraction of between 30% and 35%, equating to $92 billion to $108 billion. This assumes a longer period of sales decline.
Although there are signs of recovery in China, the industry is not expected to fully return to 2019 levels until 2022 at the earliest. By that stage, the industry could have transformed entirely.
Changing Consumer Mindsets
Since the beginning of the pandemic, one-quarter of consumers have delayed purchasing luxury items. In fact, a portion of those who have delayed purchasing luxury goods are now considering entirely new avenues, such as seeking out cheaper alternatives.
However, most people surveyed claim that they will postpone buying luxury items until they can get a better deal on price.
This frugal mindset could spark an interesting behavioral shift, and set the stage for a new category to emerge from the ashes—the second-hand luxury market.
Numerous sources claim that pre-owned luxury could in fact overtake the traditional luxury market, and the pandemic economy could very well be a tipping point.
The Future of Luxury
Medium-term market growth could be driven by a number of factors, from a global growing middle class and their demand for luxury products, as well as retailers’ sudden shift to e-commerce.
While analysts can only rely on predictions to determine the future of personal luxury, it is clear that the industry is at a crossroads.
COVID-192 months ago
The Pandemic Economy: What are Shoppers Buying Online During COVID-19?
COVID-192 months ago
The Front Line: Visualizing the Occupations with the Highest COVID-19 Risk
COVID-192 months ago
Visualizing What COVID-19 Does to Your Body
COVID-192 months ago
How COVID-19 Consumer Spending is Impacting Industries
Economy2 months ago
What is Big Tech Contributing to Help Fight COVID-19?
Entrepreneurship2 months ago
Navigating Uncertainty: Leadership Accountability in Times of Crisis
Chart of the Week2 months ago
These Charts Put the Historic U.S. Job Losses in Perspective
Money1 month ago
Making Billions: The Richest People in the World